期刊文献+

米非司酮对子宫内膜癌细胞周期时相调控的研究 被引量:2

Study on the Controlling of Mifepristone on Cell Cycle of Endometrial Carcinoma
下载PDF
导出
摘要 目的探讨抗孕激素米非司酮对子宫内膜癌细胞周期时相的调控作用.方法体外培养子宫内膜癌HHUA细胞,不同浓度米非司酮处理细胞24~96小时,流式细胞术(FCM)测定癌细胞周期分布的变化;免疫组化法观察细胞周期调控蛋白的表达变化.结果当抗孕激素米非司酮浓度≥5μmol/L作用癌细胞36小时,G1期细胞比率明显上升,S期细胞比率(SPF)降低(P<0.05);细胞周期调控蛋白p21和p16表达明显上调(P<0.05).结论抗孕激素米非司酮通过调节细胞周期相关蛋白表达使HHUA细胞阻滞于G1期,抑制癌细胞增殖. Objective To study the effect of antiprogestin mifepristone on cell cycle of endometrial carcinoma. Methods Human endometrial carcinoma HHUA cell was cultured in vitro and treated with mifepristone in different concentration for 24-96 hours. Influence of mifepristone on the cell cycle distribution were detected by using flow eytometry (FCM). The expression of protein related cell cycle was observed by immunohistoehemieal. Results Treated HHUA cell in vitro with mifepristone≥5μmol/L for 36 hours, rate of G1 phase was increased and S-phase fraction (SPF) was decreased obviously (P〈0. I)5). The expression of cell cycle related protein p21 and p16 were raised significantly (P〈0. 05). Conclusion Antiprogestins mifepristone could effectively block HHUA cells at G1 phase and inhibit the proliferation by controlling the expression of protein related cell cycle.
出处 《肿瘤防治研究》 CAS CSCD 北大核心 2005年第10期634-636,共3页 Cancer Research on Prevention and Treatment
关键词 米非司酮 子宫内膜癌 细胞周期 Mifepristone Endometrial carcinoma Cell cycle
  • 相关文献

参考文献2

二级参考文献27

  • 1Albert C. Clinical aspects of gastric cancer, in: Rustgi AK, eds.Cas:rointestinal cancer: biology, diagnosis and therapy.Philadelphia: Lippincott Raven 1995:197-216. 被引量:1
  • 2Lu JB, Sun XB, Dai DX, Zhu SK, Chang QL, Liu SZ, Duan WJ.Epidemiology of gastroenterologic cancer in Henan Province,China. World J Gastroenterol 2003; 9:2400-2403. 被引量:1
  • 3Maehara Y, Kakeji Y, Masuda T, Sakoguchi T, lmamura M,Ohgaki K, Taniguchi K, Sakurai M, Futatsugi M, Kimura Y,Nakamura T, Tokunaga E, Oki E, Ushiro S, Watanabe M, Oda S, Tanaka S, Baba H. Treatment of gastric cancer: current state and future prospect. Fukuoka Igaku Zasshi 2003; 94:285-295. 被引量:1
  • 4De Paoli A, Buonadonna A, Boz G, Lombardi D, lnnocente R,Tumolo S, Tosolini G, Rossi C, Trovo MG, Frustaci S. Combined modality treatment for locally advanced gastric cancer.Suppl Tumori 2003; 2:S58-S62. 被引量:1
  • 5Macdonald JS. Chemotherapy Jn the management of gastric cancer. J Chin Oncol 2003; 21: 276s-279s. 被引量:1
  • 6Valentini V, Cellini F, D'Angelillo RM. Combined treatments in gastric cancer: radiotherapy. Suppl Tumori 2003; 2:S39-S44. 被引量:1
  • 7Mahajan DK, London SN. Mifepristone (RU486): a review.Fertil Steril 1997; 68:967-976. 被引量:1
  • 8Liang Y, Hou M, Kallab AM, Barrett JT, El Etreby F, Schoenlein PV. Induction of antiproliferation and apoptosis in estrogen receptor negative MDA-231 human breast cancer cells by mifepristone and 4-hydroxytamoxifen combination therapy: a role for TGFbetal. Int J Oncol 2003; 23:369-380. 被引量:1
  • 9El Etreby MF, Liang Y, Wrenn RW, Schoenlein PV. Additive effect of mifepristone and tamoxifen on apoptotic pathways in MCF-7 human breast cancer cells. Breast Cancer Res Treat 1998; 51:149-168. 被引量:1
  • 10El Etreby MF, Liang Y. Effect of antiprogestins and tamoxifen on growth inhibition of MCF-7 human breast cancer cells in nude mice. Breast Cancer Res Treat 1998; 49:109-117. 被引量:1

共引文献23

同被引文献36

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部